Endpoint Clinical Acquires Bluefin to Merge RTSM With Supply Forecasting
Image
Raleigh – September 17, 2026 -- Endpoint Clinical L.P., a portfolio company of Arsenal Capital Partners, has acquired Boston-based Bluefin, a clinical supply forecasting and planning technology provider, expanding Endpoint's footprint from randomization and trial supply management (RTSM) into upstream supply chain planning.
Bluefin will keep operating independently across all RTSM platforms
Under the deal, Bluefin will continue to run as a standalone, RTSM-agnostic business, connecting with RTSM systems industry-wide rather than being folded exclusively into Endpoint's technology stack. Endpoint will provide global project management, implementation, quality and customer support resources to help sponsors deploy Bluefin's platform at scale.